Ornidazole
Not to be confused with ronidazole.
|  | |
| Systematic (IUPAC) name | |
|---|---|
| 1-Chloro-3-(2-methyl-5-nitro-1H-imidazol-1-yl)propan-2-ol | |
| Clinical data | |
| Trade names | Xynor | 
| AHFS/Drugs.com | International Drug Names | 
| Routes of administration | Oral | 
| Pharmacokinetic data | |
| Metabolism | Metabolized via the liver, excreted in the Urine and Feces | 
| Excretion | 85% of single oral dose is eliminated with 5 days - Urine (63%) and Feces (22%) | 
| Identifiers | |
| CAS Number | 16773-42-5  | 
| ATC code | G01AF06 (WHO) J01XD03 P01AB03 QP51AA03 | 
| PubChem | CID 28061 | 
| ChemSpider | 26102  | 
| UNII | 62XCK0G93T  | 
| KEGG | D05274  | 
| ChEBI | CHEBI:75176  | 
| ChEMBL | CHEMBL1449676  | 
| Chemical data | |
| Formula | C7H10ClN3O3 | 
| Molar mass | 219.625 g/mol | 
| 
 | |
| 
 | |
|   (what is this?)  (verify) | |
Ornidazole is a drug that cures some protozoan infections. It has been investigated for use in Crohn's disease after bowel resection.[1]
Synthesis is a straightforward reaction between 2-methyl-nitroimidazole and epichlorohydrin under acid catalyst conditions.[2]
References
- ↑ Rutgeerts P, Van Assche G, Vermeire S, et al. (April 2005). "Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial". Gastroenterology 128 (4): 856–61. doi:10.1053/j.gastro.2005.01.010. PMID 15825069.
- ↑ Hoffer, Max; Grunberg, Emanuel (1974). "Synthesis and antiprotozoal activity of 1-(3-chloro-2-hydroxypropyl)-substituted nitroimidazoles". Journal of Medicinal Chemistry 17 (9): 1019–1020. doi:10.1021/jm00255a026. ISSN 0022-2623.
| 
 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 
 | ||||||||||||||||||||||||||||||||||||||||||||
| 
 | ||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.